StockWatch
·

Yatharth Hospital & Trauma Care Services Ltd

BSE: 543950

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
209.55
+10.5%+46.1%
Expenditure
165.41
+9.1%+41.6%
Net Profit
37.06
+31.6%+79.6%
OPM %
23.53%
+0.75pp+3.90pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.0058.67117.35176.02234.70Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

Yatharth Q2FY27: consolidated revenue +54% YoY, margin compression caps PAT at +17%

hospital chain · healthcare · margin compression

ResultsQ2 FY2703 Nov 20263 minPharma & Healthcare

Yatharth group gets ₹43.8 Cr in final tax demands plus ₹15.9 Cr interest; appeals next, no provision booked

income tax · assessment orders · appeals

Research14 Sept 20264 minPharma & Healthcare

Record revenue, margin miss — capex drag to persist 12–18 months

acquisition playbook · capex burden · margin compression

Result verdictFollow-upQ1 FY2718 Aug 20266 minPharma & Healthcare
Latest
Board Meeting3 Nov, 2:04 pm

Yatharth Q2FY27: consolidated revenue +54% YoY, margin compression caps PAT at +17%

Consolidated revenue for Q2 FY27 rose 54.4% YoY (and 9.9% QoQ) to ₹431.42 Cr, continuing the pace set in Q1 FY27 (+52.3% YoY) and running well ahead of management's guidance to outgrow FY26's 36% full-year growth. Consolidated PAT grew a slower 17.5% YoY to ₹48.46 Cr, with profit attributable to owners at ₹50.59 Cr (EPS ₹5.25, +22.7% YoY) — the gap between the two PAT figures stems from a ₹2.13 Cr quarterly loss at minority-held new-hospital subsidiaries (five such units reported a combined ₹4.19 Cr net loss this quarter per the auditors' note), a loss borne by minority shareholders rather than the parent. Net profit margin compressed to 11.10% from 14.28% a year earlier, even as operating margin (EBITDA/revenue) held roughly flat at 23.65% versus 23.09% YoY — the squeeze sits below the EBITDA line. Finance costs jumped to ₹8.28 Cr from just ₹0.26 Cr a year ago, and depreciation rose 75% YoY to ₹33.14 Cr, both tracking the capex behind new hospitals (consolidated borrowings rose to ₹450.69 Cr from ₹253.33 Cr at FY26-end, with gross block and CWIP at ₹9,513 Cr and ₹2,421 Cr respectively). Management had flagged this dynamic on the prior call: new hospitals are only expected to reach 25-27% EBITDA margins by FY28-29, and this quarter's 23.65% OPM, though better than Q1's 23.35%, still sits under the company's stated ">24%" floor. Against the prior concall's confident, optimistic tone and the guidance to outgrow FY26's 36% revenue growth, this quarter's 54% YoY print clearly beats the topline promise, while the margin commitment is not yet met but is trending the right way sequentially. No Q2 FY27-specific street estimates for this company turned up in a search for brokerage previews, so vsStreet is unknown; FY27 full-year consensus (per analyst trackers) pegs revenue near ₹1,700 Cr (+41% YoY), a bar this quarter's run-rate is tracking ahead of. Standalone PAT was ₹37.06 Cr on standalone revenue of ₹194.91 Cr — under half of consolidated revenue — underscoring that a growing share of both growth and margin drag now sits inside subsidiaries rather than the parent entity. The quarter's biggest non-operating development was the October 15, 2026 EGM approval for Rasmalai Limited, an Advent International affiliate, to acquire a 24.9% stake in the company via preferential issue on a fully diluted basis, pending regulatory approvals. Separately, the company disclosed a ₹29.66 Cr income-tax demand covering AY2014-15 to AY2024-25 as a contingent liability, with no provision made, stating it expects substantial relief on appeal.

3 Nov 2026, 02:04 pm

Corporate Events

Board MeetingYATHARTH
2026
3Nov

Board Meeting

The meeting of the Board of Directors is scheduled to consid…

BSE Filing ↗
Board MeetingYATHARTH
2026
15Oct

Board Meeting

The Extra-Ordinary General Meeting (EGM) of the Members of t…

BSE Filing ↗
Board MeetingYATHARTH
2026
25Sep

Board Meeting

The 19th Annual General Meeting ("AGM") of the Members of Ya…

BSE Filing ↗
Board MeetingYATHARTH
2026
17Sep

Board Meeting

The Board of Directors meeting is scheduled to discuss and c…

BSE Filing ↗
DividendYATHARTH
2026
14Aug

₹0.5 / share

BSE Filing ↗
Board MeetingYATHARTH
2026
10Aug

Board Meeting

The Board of Directors meeting is scheduled to consider and …

BSE Filing ↗
Board MeetingYATHARTH
2026
25May

Board Meeting

The board meeting is scheduled to consider and approve the A…

BSE Filing ↗
Board MeetingYATHARTH
2026
5Feb

Board Meeting

consider and approve the Unaudited Financial Results (Standa…

BSE Filing ↗
Board MeetingYATHARTH
2025
5Aug

Board Meeting

Consider and approve Unaudited Financial Results (Standalone…

BSE Filing ↗
Board MeetingYATHARTH
2025
27Jan

Board Meeting

To consider and approve the Unaudited Financial Results (Sta…

BSE Filing ↗
Board MeetingYATHARTH
2024
7Nov

Board Meeting

Consider and approve the unaudited financial results, raisin…

BSE Filing ↗
Board MeetingYATHARTH
2024
13Aug

Board Meeting

consider and approve the unaudited Financial Results (Standa…

BSE Filing ↗
Board MeetingYATHARTH
2024
23May

Board Meeting

Consider and approve the Audited Financial Results

BSE Filing ↗